BioGeometry Secures Hundreds of Millions in Strategic Financing to Advance AI-Driven Life Science Platform

BioGeometry Officially Completes New Round of Strategic Financing Amounting to Hundreds of Millions of YuanRecently, BioGeometry officially completed a new round of strategic financing amounting to hundreds of millions of yuan. This round was jointly led by the Shanghai Biomedical Innovation Transformation Fund, Guoke Investment, Fortune Capital (Dachen Caizhi), and Xinglian Capital, with Gaorong Capital and the Index AI Industry Innovation Fund participating as follow-on investors. Index Capital served as the exclusive financial advisor. The proceeds from this financing will be used for the continuous iteration of GeoFlow, the company’s self-developed microscopic life science model, and to fully accelerate the construction of its high-throughput automated laboratory and the advancement of its diversified innovative drug pipeline.

BioGeometry is an AI-native biotechnology company. We leverage generative AI to build a “microscopic world model” for the life sciences, deeply integrated with automated laboratory platforms to establish an autonomous “design–experiment–learn” closed loop. Spanning antibodies, vaccines, peptides, and enzyme engineering, we enable autonomous scientific discovery in the life sciences—advancing life from being “understood” to being “designed.”